Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 101–200 of 1,000
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01586-y · Cited by 278
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
“(BAC) transgene containing the fap gene (18).”
Self-citationNanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Regulation of the anti-tumour immune response by cancer-associated fibroblasts
Harper, J., & Sainson, R. C. A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.005 · Cited by 268
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Fibroblasts as architects of cancer pathogenesis
Marsh, T., Pietras, K., & McAllister, S. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.10.013 · Cited by 264
The STING pathway and the T cell-inflamed tumor microenvironment
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.003 · Cited by 271
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials
Stephan, M. T., & Irvine, D. J. (2011) · Nano Today · doi:10.1016/j.nantod.2011.04.001 · Cited by 266
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Biasci, D., Smoragiewicz, M., Connell, C. M., Wang, Z., Gao, Y., Thaventhiran, J. E. D., Basu, B., Magiera, L., Johnson, T. I., Bax, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013644117 · Cited by 262
Self-citationDeterminants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
“It will be of great interest to study the effects of this therapeutic strategy in immunocompetent models, as well as explore the putative role of CAFs as immunosuppressors (Feig et al., 2013; Kraman et al., 2010).”
BackgroundThe double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R., & Coffman, L. G. (2019) · Translational Research · doi:10.1016/j.trsl.2019.02.006 · Cited by 242
Stromal Cells in Chronic Inflammation and Tertiary Lymphoid Organ Formation
Buckley, C. D., Barone, F., Nayar, S., Bénézech, C., & Caamaño, J. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120252 · Cited by 249
Fibroblast pathology in inflammatory diseases
Wei, K., Nguyen, H. N., & Brenner, M. B. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149538 · Cited by 236
The Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alashkar Alhamwe, B., von Strandmann, E., Slater, E. P., Bartsch, J. W., Bauer, C., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 244
“, NCT03386721) targeting the CXCL12-producing FAP+ stromal subpopulation are ongoing [199].”
BackgroundNeddylation: a novel modulator of the tumor microenvironment
Zhou, L., Jiang, Y., Luo, Q., Li, L., & Jia, L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0979-1 · Cited by 249
Tillmanns, J., Hoffmann, D., Habbaba, Y., Schmitto, J. D., Sedding, D., Fraccarollo, D., Galuppo, P., & Bauersachs, J. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.08.016 · Cited by 237
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
Alkasalias, T., Moyano-Galceran, L., Arsenian-Henriksson, M., & Lehti, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051532 · Cited by 247
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 242
Tissue Force Programs Cell Fate and Tumor Aggression
Northey, J. J., Przybyla, L., & Weaver, V. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0733 · Cited by 237
Tumor-associated fibroblasts predominantly come from local and not circulating precursors
Arina, A., Idel, C., Hyjek, E. M., Alegre, M.-L., Wang, Y., Bindokas, V. P., Weichselbaum, R. R., & Schreiber, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600363113 · Cited by 238
Recent advances in active targeting of nanomaterials for anticancer drug delivery
Dutta, B., Barick, K. C., & Hassan, P. A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102509 · Cited by 232
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02599-7 · Cited by 210
“Abbreviations BMP: Bone morphogenetic protein; CAF: Cancer-associated fibroblast; CAM-DR: Cell adhesion mediated drug resistance; CSC: Cancer stem cell; CTL: Cytotoxic T lymphocyte; ECM: Extracellular matrix; EMT: Epithelial-mesenchymal transition; FAP: Fibroblast activation protein; FGF: Fibroblast growth factor; ICI…”
BackgroundInfluentialBecht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Zhen, Z., Tang, W., Wang, M., Zhou, S., Wang, H., Wu, Z., Hao, Z., Li, Z., Liu, L., & Xie, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04150 · Cited by 219
HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation
Nitti, M., Piras, S., Marinari, U., Moretta, L., Pronzato, M., & Furfaro, A. (2017) · Antioxidants · doi:10.3390/antiox6020029 · Cited by 223
The speed of change: towards a discontinuity theory of immunity?
Pradeu, T., Jaeger, S., & Vivier, E. (2013) · Nature Reviews Immunology · doi:10.1038/nri3521 · Cited by 199
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 215
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 217
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 213
Huang, T.-X., Tan, X.-Y., Huang, H.-S., Li, Y.-T., Liu, B.-L., Liu, K.-S., Chen, X., Chen, Z., Guan, X.-Y., Zou, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322924 · Cited by 200
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 195
Tumor-induced stromal reprogramming drives lymph node transformation
Riedel, A., Shorthouse, D., Haas, L., Hall, B. A., & Shields, J. (2016) · Nature Immunology · doi:10.1038/ni.3492 · Cited by 204
Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment
Houthuijzen, J. M., & Jonkers, J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9768-3 · Cited by 205
“led to the development of FAP-based vaccines to target CAFs in a variety of tumors, including breast cancer [31, 193, 194].”
Smad3 Promotes Cancer‐Associated Fibroblasts Generation via Macrophage–Myofibroblast Transition
Tang, P. C., Chung, J. Y., Xue, V. W., Xiao, J., Meng, X., Huang, X., Zhou, S., Chan, A. S., Tsang, A. C., Cheng, A. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202101235 · Cited by 188
Ammirante, M., Shalapour, S., Kang, Y., Jamieson, C. A. M., & Karin, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416498111 · Cited by 206
“The mRNAs for CXCL13 and fibroblast activation protein (FAP), an enzyme that is expressed in mesenchymal stem cells and stromal fibroblasts (28) and that can serve as another myofibroblast marker (29), were detected only in the fibroblast fraction, not in the epithelial fraction prepared 1 wk after castration (Fig.”
BackgroundNguyen, H. N., Noss, E. H., Mizoguchi, F., Huppertz, C., Wei, K. S., Watts, G. F. M., & Brenner, M. B. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.004 · Cited by 209
“In tumor tissues, fibroblasts referred to as stromal cells can profoundly inhibit anti-tumor immune responses that are reactivated upon removal of the inhibitory stromal cells (Kraman et al., 2010).”
BackgroundLooi, C.-K., Chung, F. F.-L., Leong, C.-O., Wong, S.-F., Rosli, R., & Mai, C.-W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 202
“Depletion of FAP-expressing stromal cells resulted in a better immunological response and a lower tumor burden [29, 35],These findings may suggest therapeutics that selectively target FAP-expressing cells, but not other cancer-associated stromal cells, may result in a better prognosis.”
Grauel, A. L., Nguyen, B., Ruddy, D., Laszewski, T., Schwartz, S., Chang, J., Chen, J., Piquet, M., Pelletier, M., Yan, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19920-5 · Cited by 211
Schuberth, P. C., Hagedorn, C., Jensen, S. M., Gulati, P., van den Broek, M., Mischo, A., Soltermann, A., Jüngel, A., Marroquin Belaunzaran, O., Stahel, R., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-187 · Cited by 206
“Its expression is also associated with chronic inflammation, tissue remodeling [18] and immune modulation in the tumor tissue [19].”
BackgroundShi, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.840 · Cited by 199
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
“FAP, for example, is expressed by some tumor-infiltrating immune cells (14, 15) and is also expressed in lymph nodes (LN; refs.”
BackgroundExtracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C., & Jean, C. (2021) · Cancers · doi:10.3390/cancers13143466 · Cited by 191
Invading one step at a time: the role of invadopodia in tumor metastasis
Paz, H., Pathak, N., & Yang, J. (2014) · Oncogene · doi:10.1038/onc.2013.393 · Cited by 197
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
“CAFs promote tumour progression by exerting an influence on ECM in the TME (Levental et al., 2009; Kobayashi et al., 2010).”
BackgroundInfluentialTargeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207
“While many studies have targeted angiogenesis and inflammation/immune function, several investigations recently have focused on stromal collagenous extracellular matrix and CAFs as potential targets [27, 47-58].”
BackgroundInflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.003 · Cited by 206
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
Targeting of activated fibroblasts for imaging and therapy
Lindner, T., Loktev, A., Giesel, F., Kratochwil, C., Altmann, A., & Haberkorn, U. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0069-0 · Cited by 205
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology
Nayar, S., Campos, J., Smith, C. G., Iannizzotto, V., Gardner, D. H., Mourcin, F., Roulois, D., Turner, J., Sylvestre, M., Asam, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905301116 · Cited by 203
Self-citationCAFs and TAMs: maestros of the tumour microenvironment
Komohara, Y., & Takeya, M. (2017) · The Journal of Pathology · doi:10.1002/path.4824 · Cited by 197
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.010 · Cited by 182
“This microenvironment is prominently composed of the mononuclear phagocytic lineage (MPS) in addition to tumorassociated fibroblasts (TAFs) and a variety of additional immune infiltrates, including neutrophils and tumor-specific T cells (Hanahan and Weinberg, 2011; Kraman et al., 2010).”
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy
Vasievich, E. A., & Huang, L. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1004228 · Cited by 199
Genetically engineered mouse models of pancreatic adenocarcinoma
Guerra, C., & Barbacid, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.002 · Cited by 179
“Previous studies using mouse xenografts have illustrated that the presence of PSCs and/or CAFs enhance tumor incidence growth and metastasis of PDAC tumor cell lines (Apte and Wilson, 2012; Hwang et al., 2008; Kraman et al., 2010).”
BackgroundTumor stroma as targets for cancer therapy
Zhang, J., & Liu, J. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.003 · Cited by 187
“Kraman et al. (2010) presented that a subset of FAP-expressing stromal cells (all stained with α-SMA) are an immunosuppressive TME component.”
BackgroundThe Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 187
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx121 · Cited by 195
“Given the previously described roles for CAFs in promoting resistance to chemotherapy (64,65) and adaptive antitumor immunity (4,66), stromal depletion through NOX4 inhibition may be a useful adjunct to improve response to current chemoand immunotherapeutics in patients with a-SMA-positive CAFrich tumors.”
BackgroundInfluentialBrennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs336 · Cited by 188
Pancreatic stellate cell: Pandora's box for pancreatic disease biology
Bynigeri, R. R., Jakkampudi, A., Jangala, R., Subramanyam, C., Sasikala, M., Rao, G. V., Reddy, D. N., & Talukdar, R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i3.382 · Cited by 178
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D'Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 172
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Fibroblast activation protein: A potential therapeutic target in cancer
Liu, R., Li, H., Liu, L., Yu, J., & Ren, X. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.3.18696 · Cited by 182
“In addition, depletion of FAP cells causes rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors through a process involving interferon-c (IFN-c) and tumor necrosis factor a (TNF-a), which have previously been shown to be involved in the suppression of angiogenesis.(51) In corneal stroma, FAP c…”
BackgroundCharacterizing dedifferentiation of thyroid cancer by integrated analysis
Luo, H., Xia, X., Kim, G. D., Liu, Y., Xue, Z., Zhang, L., Shu, Y., Yang, T., Chen, Y., Zhang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf3657 · Cited by 175
Borriello, L., Nakata, R., Sheard, M. A., Fernandez, G. E., Sposto, R., Malvar, J., Blavier, L., Shimada, H., Asgharzadeh, S., Seeger, R. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2586 · Cited by 180
Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
“In addition, we uncovered an inhibitory role for CAFs regarding cancer-immune interactions, supporting the emerging concept of an immune-suppressive role for CAFs in the tumor microenvironment (Costa et al., 2018; Feig et al., 2013; Givel et al., 2018; Kraman et al., 2010; Liao et al., 2009; Yang et al., 2016; Zhang a…”
BackgroundSideras, K., Braat, H., Kwekkeboom, J., van Eijck, C. H., Peppelenbosch, M. P., Sleijfer, S., & Bruno, M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.005 · Cited by 173
“In addition CAFs secrete fibroblast activation protein (FAP-a) which further suppresses effector T cells through interfering with TNF-a and IFN-c related activation [49].”
BackgroundReengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
“The cross talk between cancer cells, HSCs/PSCs/CAFs and other cells of the tumor microenvironment (TME) regulates the expression of cytokines and exosomes that promote desmoplasia, cancer cell proliferation and stemness, angiogenesis, inflammation/immunosuppression, invasion, and metastasis (Erez et al. 2010; Kraman e…”
BackgroundPancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 173
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 170
The stromal compartments in pancreatic cancer: Are there any therapeutic targets?
Lunardi, S., Muschel, R. J., & Brunner, T. B. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.09.039 · Cited by 176
Arnold, J. N., Magiera, L., Kraman, M., & Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0150 · Cited by 166
Self-citationThe immunomodulatory properties of mesenchymal stem cells
Marigo, I., & Dazzi, F. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0267-7 · Cited by 162
“Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma permitted immunological control of growth [96].”
BackgroundLi, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 180
Roles of nonmyogenic mesenchymal progenitors in pathogenesis and regeneration of skeletal muscle
Uezumi, A., Ikemoto-Uezumi, M., & Tsuchida, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00068 · Cited by 165
“FAP+ stromal fibroblasts suppress the immune response to tumors, and elimination of FAP+ fibroblasts from tumor stroma unmasks the immune response to cancer and allows the immune system to attack tumors (Kraman et al., 2010).”
BackgroundMona, C. E., Benz, M., Hikmat, F., Grogan, T., Lückerath, K., Razmaria, A. A., Riahi, R., Slavik, R., Girgis, M. D., Carlucci, G., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262426 · Cited by 167
Lo, A., Li, C.-P., Buza, E. L., Blomberg, R., Govindaraju, P., Avery, D., Monslow, J., Hsiao, M., & Puré, E. (2017) · JCI Insight · doi:10.1172/jci.insight.92232 · Cited by 160
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer
Zhang, H., Maric, I., DiPrima, M. J., Khan, J., Orentas, R. J., Kaplan, R. N., & Mackall, C. L. (2013) · Blood · doi:10.1182/blood-2012-08-449413 · Cited by 163
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Storz, P., & Crawford, H. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.059 · Cited by 154
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
Kosti, P., Opzoomer, J. W., Larios-Martinez, K. I., Henley-Smith, R., Scudamore, C. L., Okesola, M., Taher, M. Y. M., Davies, D. M., Muliaditan, T., Larcombe-Young, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100227 · Cited by 150
“Tumor tissue, and other organs, for flow cytometry analyses were enzyme-digested to release single cells as previously described.(41) In brief, tissues were minced using scalpels, and then single cells were liberated by incubation for 60 mins at 37 C with 1 mg/ml Collagenase I from Clostridium Histolyticum (Sigma-Aldr…”
MethodResultSelf-citationFibroblasts Fuel Immune Escape in the Tumor Microenvironment
De Jaeghere, E. A., Denys, H. G., & De Wever, O. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.009 · Cited by 160
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 156
“expression and/or activity of FAP [37,80,81], PDGFR [36,82], Smo [8,49], CXCR4 [38], NF-κB [24] or Ets [48,53] in CAFs attenuated tumour growth, decreased angiogenesis, improved intratumoural drug delivery and/or restored anti-tumour immune responses.”
BackgroundInfluentialCAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 168
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 158
Preclinical murine tumor models: A structural and functional perspective
Guérin, M. V., Finisguerra, V., den Eynde, B. J. V., Bercovici, N., & Trautmann, A. (2020) · eLife · doi:10.7554/elife.50740 · Cited by 166
“After tumor initiation, stromal cells may be recruited by the nascent tumor from neighboring normal tissue or may differentiate from mesenchymal cells arriving through the blood from the bone marrow (Bucala et al., 1994; Kraman et al., 2010).”
BackgroundDuperret, E. K., Trautz, A., Ammons, D., Perales-Puchalt, A., Wise, M. C., Yan, J., Reed, C., & Weiner, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2033 · Cited by 152
Zheng, H., Liu, H., Ge, Y., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02252-9 · Cited by 173
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 152
Shangguan, L., Ti, X., Krause, U., Hai, B., Zhao, Y., Yang, Z., & Liu, F. (2012) · STEM CELLS · doi:10.1002/stem.1251 · Cited by 146
Cancer-associated fibroblasts: how do they contribute to metastasis?
Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09959-0 · Cited by 168
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 152
Self-citationThe Diverse Roles of Heme Oxygenase-1 in Tumor Progression
Hoang, K. N. L., Anstee, J. E., & Arnold, J. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658315 · Cited by 168
“Specific conditional depletion of FAP TAMs, using diphtheria toxin in a bone marrow chimera of a FAP/diphtheria toxin receptor (DTR) transgenic mouse (54), permitted immunological control of tumor growth (26).”
BackgroundMethodSelf-citationCancer-associated fibroblasts: The chief architect in the tumor microenvironment
Sarkar, M., Nguyen, T., Gundre, E., Ogunlusi, O., El-Sobky, M. H., Giri, B., & Sarkar, T. R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1089068 · Cited by 165
Denton, A. E., Roberts, E. W., Linterman, M. A., & Fearon, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412910111 · Cited by 150
Self-citation
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.